The Monarch eTNS System (Neurosigma) is a medical device designed to provide treatment for pediatric Attention Deficit Hyperactivity Disorder (ADHD) in children between the ages of 7 and 12 years old. This innovative device serves as a “monotherapy,” meaning it can be used as a standalone treatment option for ADHD in children who are not currently taking prescription medications for the condition. It offers a non-invasive, non-pharmacological approach to address ADHD symptoms in this specific age group.
The device is intended to be used at home, and its usage should be supervised by a caregiver during periods of sleep. This feature allows for convenience and flexibility for both the child and their caregiver, as it eliminates the need for frequent visits to a medical center for treatment sessions.
As with any medical treatment, Neurosigma may have side effects. The most commonly observed side effects during its use include drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache, and fatigue. These side effects are generally considered mild and manageable, and they typically subside over time with continued use of the device.
It's important to note that, as of now, no serious adverse reactions have been reported with the use of the Neurosigma. However, individuals and caregivers should always follow the instructions for use provided by healthcare professionals to ensure safe and effective usage.
The Monarch eTNS System (Neurosigma) requires a prescription for patient treatment, emphasizing the importance of a medical evaluation before initiating the use of this device. A healthcare provider will assess the child's individual condition and suitability for this treatment option, considering factors such as the severity of ADHD symptoms, medical history, and any other existing treatments or medications.
To maximize the benefits of the Monarch eTNS System, regular communication with healthcare professionals is essential. The child's progress should be monitored, and any concerns or changes in symptoms should be promptly discussed with the healthcare provider to ensure the most appropriate and effective management of ADHD.
Overall, the Monarch eTNS System represents an innovative and promising approach to address ADHD symptoms in children aged 7 to 12 years old. Its non-invasive nature and home-based use offer potential advantages for families seeking alternative treatment options for pediatric ADHD.
Here at Blue Umbrella Psychiatry, we want to offer as many treatment options as possible to be able to meet the care needs of as many individuals as possible. We’ve added Monarch eTNS System (Neurosigma) as part of our ever-growing umbrella of options for our valued patients to receive coverage and care from.
For more information or answers to any questions, consult your prescriber or visit
